Related Experiment Video
Updated: Jul 14, 2026
09:38
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
[Immunosuppression with monoclonal antibodies in multiple sclerosis]
1Clinique neurologique, CHU de Lille, Hôpital Roger-Salengro, 59037 Lille Cedex, France. pvermersch@chru-lille.fr
Revue Neurologique
|July 4, 2007
Summary
Natalizumab, a monoclonal antibody, significantly reduces relapses and disability progression in multiple sclerosis. However, long-term safety remains unknown, with rare but serious side effects observed.
Area of Science:
- Neuroimmunology
- Pharmacology
Context:
- Multiple sclerosis (MS) treatments have evolved from interferon beta and glatiramer acetate.
- Natalizumab represents a significant advancement as a targeted therapy for relapsing-remitting MS.
Purpose:
- To evaluate the efficacy and safety of natalizumab in patients with relapsing-remitting multiple sclerosis.
- To assess the impact of natalizumab on clinical relapses, disability progression, and MRI-detected lesions.
Summary:
- Natalizumab, a monoclonal antibody targeting alpha4B1 integrin, effectively reduces T-cell adhesion and subsequent inflammation.
- A randomized, placebo-controlled study demonstrated a 68% reduction in relapses and a 42% reduction in disability progression over two years.
- MRI data showed a 92% decrease in gadolinium-enhanced lesions in the natalizumab group compared to placebo.
Impact:
- Natalizumab offers a new therapeutic option for MS, demonstrating substantial clinical and radiological benefits.
- The long-term safety profile of natalizumab requires further investigation due to rare but severe adverse events like progressive multifocal leukoencephalopathy.
- The success of natalizumab highlights the potential of monoclonal antibodies in MS treatment, paving the way for other agents like alemtuzumab.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
01:25Immunodeficiency Diseases
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
There are three main causes of immunodeficiency disorders...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...